China’s Helicobacter Pylori Vaccine Completes Phase III Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
According to China's Ministry of Science and Technology, the Third Military Medical University of the PLA has successfully developed an oral recombinant Helicobacter pylori vaccine. The world's first such vaccine, the product has completed Phase III clinical trials and obtained the country's new drug certification. Trial results showed the vaccine to be effective and safe, with a protection rate of 72 percent in preventing H. pylori infection. The bacteria, which afflict some 50 percent of people in developing countries, cause gastric ulcers and show close correlation with stomach cancer. The developer of the vaccine, along with investors, are working hard to bring it to market as soon as possible. (Click here for more - Chinese Language)
You may also be interested in...
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.